<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxycodone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxycodone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxycodone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10939" href="/d/html/10939.html" rel="external">see "Oxycodone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12666" href="/d/html/12666.html" rel="external">see "Oxycodone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58073977"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Requiring Updates to Opioid Prescribing Information</span>
<span class="collapsible-date">April 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has issued a drug safety communication to announce safety-related updates to the prescribing information for immediate-release (IR) and extended-release (ER)/long-acting (LA) opioid analgesics, including updates to Boxed Warnings, Indications and Usage, Dosage and Administration, Warnings and Precautions, and the Medication Guide. These safety labeling changes are intended to provide clarity on appropriate patient populations for opioid treatment, appropriate dosage and administration, and updated information on the risks associated with opioid use. The required safety labeling changes include stating:</p>
<ul>
<li>
<p style="text-indent:0em;">the risk of overdose increases as the dosage increases for all opioid pain medicines;</p></li>
<li>
<p style="text-indent:0em;">IR opioids should not be used for an extended period of time unless a patient's pain remains severe enough to require them and alternative treatment options continue to be inadequate;</p></li>
<li>
<p style="text-indent:0em;">many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine;</p></li>
<li>
<p style="text-indent:0em;">it is recommended to reserve ER/LA opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate; and</p></li>
<li>
<p style="text-indent:0em;">a warning about opioid-induced hyperalgesia (OIH), including information on differentiating OIH symptoms from those of opioid tolerance and withdrawal.</p></li></ul>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use&amp;token=W5X7myh%2Fi%2FQGr76L%2FoSZbu%2BwYKvRHJDB8O4e79tNg%2FJelrlNqz4gv2DJCwSZVkI3gE10g96a4t1z3Z59rSO%2Fb6izsjmacse6U4o7Ho29jYziQVHf0MYzW7j8%2B8LrQ2%2B4Ru4vvCtWrdS3FrWL%2B0kz4ajIBlnws%2B6VB3AxZWaliq8%3D&amp;TOPIC_ID=9729" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5709186"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Addiction, abuse, and misuse:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Oxycodone exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing oxycodone and monitor all patients regularly for the development of these behaviors or conditions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid analgesic risk evaluation and mitigation strategy (REMS)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the FDA has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to health care providers. Health care providers are strongly encouraged to complete a REMS-compliant education program and counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products; emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and consider other tools to improve patient, household, and community safety.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Life-threatening respiratory depression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, or fatal respiratory depression may occur with use of oxycodone. Monitor for respiratory depression, especially during initiation of oxycodone or following a dose increase. Instruct patients to swallow oxycodone tablets whole; crushing, chewing, or dissolving oxycodone ER tablets can cause rapid release and absorption of a potentially fatal dose of oxycodone.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Accidental ingestion:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Accidental ingestion of even one dose of oxycodone, especially by children, can result in a fatal overdose of oxycodone.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neonatal opioid withdrawal:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prolonged use of oxycodone during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cytochrome P450 3A4 interaction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The concomitant use of oxycodone with all cytochrome P450 (CYP-450) 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used CYP3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving oxycodone and any CYP3A4 inhibitor or inducer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of oxycodone and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of medication errors (oral solution):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ensure accuracy when prescribing, dispensing, and administering oxycodone oral solution. Dosing errors due to confusion between mg and mL, and other oxycodone oral solutions of different concentrations can result in accidental overdose.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F204903"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Oxaydo;</li>
<li>OxyCONTIN;</li>
<li>Roxicodone;</li>
<li>RoxyBond;</li>
<li>Xtampza ER</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867796"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Oxycodone CR [DSC];</li>
<li>APO-Oxycodone CR;</li>
<li>Oxy-IR;</li>
<li>OxyNEO;</li>
<li>PMS-OxyCODONE;</li>
<li>PMS-OxyCODONE CR;</li>
<li>Supeudol;</li>
<li>Supeudol 10;</li>
<li>Supeudol 20</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F204935"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Opioid</li></ul></div>
<div class="block doa drugH1Div" id="F204907"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Consider prescribing naloxone for patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, patients with sleep-disordered breathing, higher opioid dosages (≥50 morphine milligram equivalents [MME]/day orally [equivalent to oxycodone ≥33 mg/day]), and/or concomitant benzodiazepine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26827847','lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26827847','lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing provided is based on typical doses; some patients may require higher or lower doses. Individualize dosing based on patient-specific factors (eg, comorbidities, severity of pain, degree of opioid experience/tolerance) and titrate to patient-specific treatment goals (eg, improvement in function and quality of life, decrease in pain using a validated pain rating scale). Use the lowest effective dose for the shortest period of time.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Opioids may be part of a comprehensive, multimodal, patient-specific treatment plan for managing moderate to severe pain. Maximize nonopioid analgesia, if appropriate, prior to initiation of opioid analgesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391','lexi-content-ref-28267689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391','lexi-content-ref-28267689'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b39f70aa-4cba-40b7-9987-46b6d87bfe98">Acute pain in opioid-naive patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain in opioid-naive patients: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing: Note: </b>For acute non–cancer-related pain severe enough to require an opioid, utilize multimodal pain control, maximize nonopioid analgesics, and limit the quantity prescribed to the expected duration of pain severe enough to require opioids. Do not use long-acting preparations for treatment of acute pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26827847','lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26827847','lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 5 mg every 4 to 6 hours as needed; adjust dose according to patient response. Usual dosage range: 5 to 15 mg every 4 to 6 hours as needed. If usual dose and frequency is insufficient, reassess patient and reconsider pain management strategies. For outpatient use, usually up to 20 mg/day for moderate pain or up to 30 mg/day for severe pain will suffice. Dosing is based on severity of pain and patient-specific factors; reduced dosing may be indicated in patients with comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-PAMI.1','lexi-content-ref-Pino.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-PAMI.1','lexi-content-ref-Pino.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Rectal [Canadian product]:</b> Usual dosage range: One (10 or 20 mg) suppository up to 3 to 4 times daily as needed. If usual dose and frequency is insufficient, reassess patient and reconsider pain management strategies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pino.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pino.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20988d63-1f18-4ce7-86c9-a1f05d9c20bb">Acute pain in patients on chronic opioid therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain (eg, breakthrough cancer pain) in patients on chronic opioid therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b>
<b>Oral:</b> Usual dose: In conjunction with the scheduled opioid, administer 5% to 15% (rarely up to 20%) of the 24-hour oxycodone requirement (or MME) as needed using an IR formulation every 4 to 6 hours with subsequent dosage adjustments based upon response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30254187','lexi-content-ref-Carr.1','lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30254187','lexi-content-ref-Carr.1','lexi-content-ref-Portenoy.1'])">Ref</a></span>). <b>Note: </b>If chronic opioid is not oxycodone, use MME calculations cautiously due to lack of complete cross-tolerance; generally, reduce calculated dose by 25% to 50%; conversions from methadone are highly variable and require extreme caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4f8a1e7-d904-40bc-b064-4329caccf294">Acute postoperative pain, postoperative recovery/postanesthesia care unit</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute postoperative pain, postoperative recovery/postanesthesia care unit</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Optimize multimodal perioperative pain management (eg, regional or local anesthesia, nerve blocks, nonopioid analgesics, other adjuvants) to minimize opioid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buys.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buys.1'])">Ref</a></span>). Refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Opioid-naive patients: Immediate release: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>Usual dosage range: 5 to 10 mg every 4 to 6 hours as needed. If usual dose and frequency is insufficient, reassess patient and reconsider pain management strategies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buys.1','lexi-content-ref-Carvalho.1','lexi-content-ref-28226340','lexi-content-ref-PAMI.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buys.1','lexi-content-ref-Carvalho.1','lexi-content-ref-28226340','lexi-content-ref-PAMI.1','lexi-content-ref-manu.1'])">Ref</a></span>). Some experts use 5 to 10 mg every 3 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buys.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buys.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cde2d6a9-5930-4b05-818a-a638a59289ef">Chronic pain, including chronic cancer pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic pain, including chronic cancer pain:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Before starting opioid therapy for chronic pain, establish realistic goals for pain and function, and consider how therapy will be discontinued if benefits do not outweigh risks. Opioids, including oxycodone, are <b>not</b> the preferred therapy for chronic noncancer pain due to insufficient evidence of benefit and risk of serious harm; nonpharmacologic treatment and nonopioid analgesics are preferred, with the exception of chronic pain from active cancer, sickle cell disease, and end-of-life care. Consider opioids, including oxycodone, <b>only</b> in patients who experience clinically meaningful improvement in pain and function that outweighs patient safety risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Opioid-naive patients: </b>For noncancer pain, establish oxycodone requirement using IR formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>). In patients with cancer pain, may switch to a long-acting formulation earlier in the course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Noncancer or cancer pain:</b>
<b>Immediate release:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral: </b>Initial: 2.5 to 10 mg every 4 to 6 hours as needed or scheduled around the clock (eg, cancer pain); adjust dose according to patient response (see "Titration" below). Usual maintenance dosage range: 5 to 15 mg every 4 to 6 hours as needed or scheduled around the clock. If usual dose and frequency is insufficient, reassess patient and reconsider pain management strategies. Dosing is based on severity of pain and patient-specific factors; start at the lower end of dosing range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-PAMI.1','lexi-content-ref-Portenoy.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-PAMI.1','lexi-content-ref-Portenoy.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Titration: </b></p>
<p style="text-indent:-2em;margin-left:14em;">
<b>Noncancer pain: </b>Adjust dose according to patient response; if needed, increase the dose slowly in increments of no more than 25% to 50% of the total daily dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenquist.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenquist.1'])">Ref</a></span>). <b>Note:</b> Dosages ≥50 morphine milligram equivalents (MME)/day (equivalent to oxycodone ≥33 mg/day) are likely to not have increased benefits in pain relief or function relative to overall risks. To reduce risk of overdose in noncancer pain (excluding patients with sickle cell disease and palliative care), readdress pain and reassess evidence of individual benefits and risks when increasing opioid dosage to ≥50 MME/day (equivalent to oxycodone ≥33 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:14em;">
<b>Cancer pain: </b>Adjust dose according to patient response; if needed, increase the fixed scheduled dose by 30% to 100% of the total dose taken in the prior 24-hour period including total amount of rescue medication used; if pain score decreased and functional assessment improved, continue current effective dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21543825','lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21543825','lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Rectal [Canadian product]: </b>Usual dosage range: One (10 or 20 mg) suppository up to 3 to 4 times daily as needed. If usual dose and frequency is insufficient, reassess patient and reconsider pain management strategies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Opioid-tolerant patients (also refer to "Dose Conversions for Pain Management"):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Extended release: </b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: Dosage forms: </b>Dose of ER capsules is expressed as oxycodone base and dose of ER tablets is expressed as oxycodone hydrochloride; 9 mg of oxycodone base is equivalent to 10 mg oxycodone hydrochloride. Oxycodone ER capsules and ER tablets are not bioequivalent; monitor for changes in efficacy or tolerability and adjust dose if needed. <b>Place in therapy: </b>Although manufacturer's labeling contains directions for initiating ER oxycodone products in patients who are opioid-naive with chronic pain, these preparations should not be used as initial therapy. Instead, initiate treatment with an IR preparation to more accurately determine the daily opioid requirement and decrease the risk of overdose. Unless pain is associated with cancer, palliative care, or sickle cell disease, reserve ER opioids for patients who have received IR opioids daily for ≥1 week yet continue to experience severe, continuous pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">ER tablet (oxycodone hydrochloride): <b>Oral:</b> See "Dose Conversions for Pain Management." Calculated dose may be administered every 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">ER capsule (oxycodone base): <b>Oral: </b>See "Dose Conversions for Pain Management." Calculated dose may be administered every 12 hours. Maximum dose: 288 mg/day; safety of excipients in higher daily doses has not been established.</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Titration: </b>After initiation of oxycodone ER, adjust dose in increments of 25% to 50% no more frequently than every 1 to 2 days until desired pain control. Patients may require rescue doses of an IR analgesic during dose titration. Observe for signs and symptoms of opioid withdrawal or signs of oversedation/toxicity; if unacceptable adverse reactions occur, reduce the dose. Dosages ≥50 MME/day (equivalent to oxycodone ≥33 mg/day) are likely to not have increased benefits in pain relief or function relative to overall risks. To reduce risk of overdose in noncancer pain (excluding patients with sickle cell disease and palliative care), readdress pain and reassess evidence of individual benefits and risks when increasing opioid dosage to ≥50 MME/day (equivalent to oxycodone ≥33 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>). <b>Note:</b> Some clinicians have reported better efficacy with more frequent dosing (ie, every 8 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17244106','lexi-content-ref-15322444','lexi-content-ref-16870075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17244106','lexi-content-ref-15322444','lexi-content-ref-16870075'])">Ref</a></span>); however, dosing more frequently than every 12 hours is not recommended by the manufacturer and safety has not been established.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dose conversions for pain management: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents for patients on scheduled doses of opioids. Multiple factors must be considered for safely individualizing conversion of opioid analgesia. In general, for noncancer pain, the decision to convert from an IR to an ER formulation should be individualized and reserved for those with severe continuous pain who have been taking opioids for ≥1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Converting from IR oxycodone to ER oxycodone preparations: </i>Total daily oral oxycodone dose may be administered in 2 divided doses. <b>Note: </b>Dose of ER capsules is expressed as oxycodone base and the dose of ER tablets and IR formulations is expressed as oxycodone hydrochloride; 9 mg of oxycodone base is equivalent to 10 mg oxycodone hydrochloride.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Converting between ER oxycodone preparations: </i>Dose of ER capsules is expressed as oxycodone base and the dose of ER tablets is expressed as oxycodone hydrochloride; 9 mg of oxycodone base is equivalent to 10 mg oxycodone hydrochloride. Oxycodone ER capsules and ER tablets are not bioequivalent; monitor for changes in efficacy or tolerability and adjust dose if needed. <b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Converting to/from oxycodone to/from a different opioid (parenteral or oral): </i>Refer to published equianalgesic opioid conversion data (or institutional protocols) for guidance. Conversion ratios are only approximations and substantial interpatient variability exists; therefore, it is safer to underestimate a patient’s daily oral requirement and provide breakthrough pain relief with IR formulations than to risk overestimating daily requirements. <b>When switching to a new opioid (except to/from methadone), reduce initial daily calculated equianalgesic dose of the new opioid by 25% to 50% to adjust for lack of complete mu receptor cross-tolerance</b> (conversions to/from methadone are highly variable and require extreme caution) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Converting from transdermal fentanyl to oxycodone ER: </i>Remove fentanyl patch at least 18 hours prior to starting oxycodone ER. The manufacturer suggests a conservative conversion approach of substituting each fentanyl 25 mcg/hour transdermal patch with 9 mg every 12 hours (oxycodone ER capsule) or 10 mg every 12 hours (oxycodone ER tablets). Systematic assessment of this suggested conversion has not been completed; monitor patients closely.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Converting from methadone to oxycodone ER:</i> Extreme caution and close monitoring is required when converting methadone to another opioid. Ratio between methadone and other opioid agonists varies widely according to previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation or tapering of therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b> When reducing the dose, discontinuing, or tapering long-term opioid therapy, the dose should be gradually tapered. An optimal tapering schedule has not been established. Individualize tapering based on discussions with patient to minimize withdrawal, while considering patient-specific goals and concerns and the opioid's pharmacokinetics. Proposed initial schedules range from slow (eg, 10% reduction per week or 10% reduction per month depending on duration of long-term therapy) to rapid (eg, 25% to 50% reduction every few days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-36327391'])">Ref</a></span>). Slower tapers may be appropriate after long-term use (eg, &gt;1 year), whereas more rapid tapers may be appropriate in patients experiencing severe adverse effects. During tapering, patients may be at an increased risk of overdose if they return to their original (or higher) opioid dose or use illicit opioids, due to rapid loss of tolerance; consider prescribing naloxone. Monitor carefully for signs/symptoms of withdrawal. If the patient displays withdrawal symptoms, consider slowing the taper schedule; alterations may include increasing the interval between dose reductions, decreasing amount of daily dose reduction, pausing the taper and restarting when the patient is ready, and/or coadministration of an alpha-2 agonist (eg, clonidine) to blunt autonomic withdrawal symptoms and other adjunctive agents to treat GI symptoms and muscle spasms, as needed. Continue to offer nonopioid analgesics as needed for pain management during the taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991482"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>There are no specific dose adjustments provided in the manufacturer's labeling. Oxycodone is excreted as parent drug (~10%) and as active to weakly active metabolites (~47%) with varying degrees of analgesic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30652261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30652261'])">Ref</a></span>); half-life is prolonged and accumulation of active metabolites occurs in patients with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17330696','lexi-content-ref-8695073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17330696','lexi-content-ref-8695073'])">Ref</a></span>). Use of other opioids may be preferred for management of severe pain in patients with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30833302','lexi-content-ref-27881247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30833302','lexi-content-ref-27881247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> When making dose adjustments for the rectal formulation [Canadian product], do not break, crush, cut, or dissolve the suppositories.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;60 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral, rectal [Canadian product]:</b> Initial: Administer 50% to 75% of usual dose no more frequently than every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30652261','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30652261','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution; titrate gradually based on patient response and adverse effects.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> Initial: Administer 50% to 75% of usual dose every 12 to 24 hours; if the reduced dose is less than smallest available dosage form, consider alternative analgesic. Use with caution; titrate gradually based on patient response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30652261','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30652261','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral, rectal [Canadian product]:</b> Initial: Administer 50% of usual dose no more frequently than every 8 hours. Use with caution; titrate gradually based on patient response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30652261','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30652261','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> ER formulations should preferably be avoided in patients with severe impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25788766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25788766'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Slightly dialyzable (10.6%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30189012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30189012'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral, rectal [Canadian product]:</b> Initial: Administer 50% of usual dose no more frequently than every 8 hours; titrate gradually based on patient response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution; cases of oxycodone toxicity have been reported in hemodialysis patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17330696','lexi-content-ref-25689360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17330696','lexi-content-ref-25689360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> ER formulations should preferably be avoided in patients with severe impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25788766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25788766'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral, rectal [Canadian product]:</b> Initial: Administer 50% of usual dose no more frequently than every 8 hours; titrate gradually based on patient response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> ER formulations should preferably be avoided in patients with severe impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25788766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25788766'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Close monitoring of response (analgesia) and adverse reactions (eg, sedation, CNS and respiratory depression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral, rectal [Canadian product]:</b> Initial: Administer 50% of usual dose no more frequently than every 6 hours; titrate gradually based on patient response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response (analgesia) and adverse reactions (eg, sedation, CNS and respiratory depression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral, rectal [Canadian product]:</b> Initial: Administer 50% of usual dose no more frequently than every 6 hours; titrate gradually based on patient response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Avoid use.</p></div>
<div class="block doha drugH1Div" id="F50988828"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Immediate release</i>: Initiate therapy at 33% to 50% the usual dosage and titrate carefully. For patients with severe impairment, consider extending the dosing interval based on response and tolerability (eg, every 6 to 12 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30992804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30992804'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Extended release tablets</i> or <i>Extended release capsules</i>: Initial: Initiate oxycodone ER with 33% to 50% of the calculated recommended dose. If reduced dose is less than smallest available dosage form consider alternative analgesic.</p></div>
<div class="block doe drugH1Div" id="F204908"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Minimize opioid use in older adults unless for the management of severe acute pain. Opioids are associated with an increased risk of falls and inducing or worsening delirium in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing. Initiate therapy at low end of dosing range and use caution.</p></div>
<div class="block dop drugH1Div" id="F204921"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12666" href="/d/html/12666.html" rel="external">see "Oxycodone: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: Doses should be titrated to appropriate effect.</b> Multiple concentrations of oral solution available (20 mg/mL and 1 mg/mL); the <b>highly concentrated formulation (20 mg/mL) should only be used in opioid-tolerant patients (taking ≥30 mg/day of oxycodone or equivalent for ≥1 week)</b>. Orders for oxycodone oral solutions (20 mg/mL or 1 mg/mL) should be clearly written to include the intended dose (in mg not mL) and the intended product concentration to be dispensed to avoid potential dosing errors:</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="661b3bdb-4a27-4b14-b24e-151bfa44d126">Analgesia, moderate to severe pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia, moderate to severe pain:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≤6 months: Immediate release: Oral solution (1 mg/mL): Oral: Initial dose: 0.025 to 0.05 mg/kg/dose every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12362012','lexi-content-ref-Cote.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12362012','lexi-content-ref-Cote.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;50 kg: Immediate release: Oral: Initial dose: 0.1 to 0.2 mg/kg/dose every 4 to 6 hours as needed; for severe pain some experts have recommended an initial dose of 0.2 mg/kg; usual maximum dose range: 5 to 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-APS.2','lexi-content-ref-12362012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-APS.2','lexi-content-ref-12362012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥50 kg: Immediate release: Oral: Initial dose: 5 to 10 mg every 4 to 6 hours as needed; for severe pain an initial dose of 10 mg may be used; usual maximum dose: 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.2','lexi-content-ref-12362012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.2','lexi-content-ref-12362012'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6f65896-c9ff-41a0-a671-226a94fe12e7">Analgesia, severe pain requiring around-the-clock long-term opioid therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia, severe pain requiring around-the-clock long-term opioid therapy: Note:</b> Use only in pediatric patients ≥11 years of age who are already receiving opioid therapy for ≥5 consecutive days, tolerating a minimum daily opioid dose of ≥20 mg of oxycodone orally or its equivalent at least for the 2 days immediately prior to starting extended-release oxycodone tablets, and for which alternative treatment options are inadequate. Prior to initiation, all other around-the-clock opioid therapy must be discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥11 years and Adolescents: Extended-release tablets (eg, OxyContin): Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose:</i> Based on current opioid regimen dose; use the following conversion factor table and equation to convert the current opioid(s) daily dose to the extended-release oxycodone tablet daily dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Substantial interpatient variability exists due to patient specific factors, relative potency of different opioids, and dosage forms; therefore, it is preferable to underestimate the initial 24-hour oral oxycodone requirements and utilize rescue medication (immediate-release opioid):</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose of extended-release oxycodone tablets every 12 hours = (mg/day of current opioid regimen X conversion factor)/2</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Dose calculations or adjustments for specific clinical scenarios:</i></p>
<p style="text-indent:-2em;margin-left:12em;">• If rounding is necessary, numerical value should be rounded <b>down</b> to the nearest tablet strength. If calculated <b>daily</b> dose is &lt;20 mg, do not start extended-release oxycodone tablet as there is no safe tablet strength available.</p>
<p style="text-indent:-2em;margin-left:12em;">• If more than one opioid in the regimen, calculate the approximate extended-release oxycodone tablet dose for each opioid and sum the totals for the approximate total <b>daily</b> extended-release oxycodone tablet dose, then divide by 2 for the 12-hour extended-release oxycodone dose.</p>
<p style="text-indent:-2em;margin-left:12em;">• If current opioid regimen includes a fixed-dose opioid/nonopioid dosage form (eg, hydrocodone/acetaminophen), only the mg of opioid should be used in the conversion calculations.</p>
<p style="text-indent:-2em;margin-left:12em;">• If patient receiving concomitant CNS depressants, reduce extended-release oxycodone tablet starting dose by <sup>1</sup>/<sub>3</sub> to <sup>1</sup>/<sub>2</sub> the calculated initial dose.</p>
<p style="text-indent:-2em;margin-left:12em;">• If asymmetric dosing, the higher dose should be scheduled as the morning dose, and the lower dose 12 hours later.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> The following conversion table should <b>ONLY</b> be used to convert opioid doses to extended-release oxycodone tablet (not from extended-release oxycodone tablet to other opioids; it is <b>NOT</b> a table of equianalgesic doses as it may overestimate initial dose).</p>
<table border="1" frame="border" rules="all" style="margin-left:12em;">
<caption>
<b>Conversion Factor for Calculating Initial Extended-Release Oxycodone Tablet Dose in Pediatric Patients ≥11 Years</b></caption>
<colgroup><col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="left" rowspan="2">
<p style="text-indent:0em;">Current opioid regimen to be converted to extended-release oxycodone tablet</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Conversion factor</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Oral</p></th>
<th align="left">
<p style="text-indent:0em;">Parenteral<sup>a</sup></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;">Oxycodone</p></td>
<td align="left">
<p style="text-indent:0em;">1</p></td>
<td align="left">
<p style="text-indent:0em;">--</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hydrocodone</p></td>
<td align="left">
<p style="text-indent:0em;">0.9</p></td>
<td align="left">
<p style="text-indent:0em;">--</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hydromorphone</p></td>
<td align="left">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Morphine</p></td>
<td align="left">
<p style="text-indent:0em;">0.5</p></td>
<td align="left">
<p style="text-indent:0em;">3</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Tramadol</p></td>
<td align="left">
<p style="text-indent:0em;">0.17</p></td>
<td align="left">
<p style="text-indent:0em;">0.2</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> For patients receiving high-dose parenteral opioids, a more conservative conversion factor should be applied (ie, lower numerical conversion factor); for example, for high-dose parenteral morphine, a conversion of 1.5 should be used for calculations instead of 3.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:10em;">
<i>Conversion from fentanyl patch to extended-release oxycodone tablet:</i> Limited data available: Children ≥11 years and Adolescents: <b>Note:</b> Remove fentanyl patch ≥18 hours prior to starting extended-release oxycodone. Initial dose based on current opioid regimen dose; the manufacturer suggests using the conservative conversion factor of 10 mg every 12 hours of extended-release oxycodone tablet for each 25 mcg/hour fentanyl transdermal patch; systemic assessment of this suggested conversion has not been completed, monitor patients closely.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i> Dosage adjustment (titration): After initiation of extended-release oxycodone tablet, adjust dose in small increments (up to 25% of current total daily dosage) no more frequently than every 1 to 2 days until desired pain control; patients may require rescue doses of an immediate-release analgesic during dose titration. Observe for signs and symptoms of opioid withdrawal or signs of oversedation/toxicity; if unacceptable adverse reactions occur, the subsequent dose may be reduced.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> When discontinuing chronic opioid therapy, the dose should be gradually tapered down. An optimal universal tapering schedule for all patients has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26987082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26987082'])">Ref</a></span>). Specific pediatric protocols are lacking; based on experience in adults, proposed schedules range from slow (eg, 10% reductions per week) to rapid (eg, 25% to 50% reduction every few days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>). Tapering schedules should be individualized to minimize opioid withdrawal while considering patient-specific goals and concerns as well as the pharmacokinetics of the opioid being tapered. An even slower taper may be appropriate in patients who have been receiving opioids for a long duration (eg, years), particularly in the final stage of tapering, whereas more rapid tapers may be appropriate in patients experiencing severe adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26987082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26987082'])">Ref</a></span>). Monitor carefully for signs/symptoms of withdrawal. If the patient displays withdrawal symptoms, consider slowing the taper schedule; alterations may include increasing the interval between dose reductions, decreasing amount of daily dose reduction, or pausing the taper and restarting when the patient is ready (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26987082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26987082'])">Ref</a></span>). Continue to offer nonopioid analgesics as needed for pain management during the taper; consider nonopioid adjunctive treatments for withdrawal symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151119"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">In general, oxycodone clearance may be decreased in patients with renal impairment; initiate therapy at low end of dosing range.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer 50% of dose posthemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release tablets (eg, OxyContin): Children ≥11 years and Adolescents: CrCl &lt;60 mL/minute: Serum concentrations are increased ~50%. Initiate at the low end of the dosage range (use caution); adjust dose as clinically indicated. Doses of 33% to 50% of usual initial dosing have been recommended; if the reduced dose is less than smallest available dosage form, consider alternative analgesic.</p></div>
<div class="block dohp drugH1Div" id="F51151120"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: There are no dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, may consider a conservative approach of reduced initial doses; adjust dose based on clinical response.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release tablets (eg, OxyContin): Children ≥11 years and Adolescents: Initial: One-third (<sup>1</sup>/<sub>3</sub>) to one-half (<sup>1</sup>/<sub>2</sub>) of the usual starting dose; carefully titrate dose to appropriate effect. If reduced dose is less than smallest available dosage form, consider alternative analgesic.</p></div>
<div class="block arsc drugH1Div" id="F58757490"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced constipation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opioid-induced <b>constipation</b> (OIC) is the most common subtype of opioid-induced bowel dysfunction, which is a broader term that encompasses additional GI opioid-induced adverse reactions including nausea, vomiting, and gastroesophageal reflux. Symptoms of OIC may include decreased frequency of bowel movements, straining to pass bowel movements, a sense of incomplete evacuation, and/or hard stools (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30340754','lexi-content-ref-30788113','lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30340754','lexi-content-ref-30788113','lexi-content-ref-30778756'])">Ref</a></span>). Tolerance does not develop to OIC (Müller-Lissner 2017, Rossi 2019). Symptoms are reversible after discontinuation of the opioid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28034973','lexi-content-ref-11755892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28034973','lexi-content-ref-11755892'])">Ref</a></span>). OIC is the most common reason for discontinuation reported by patients and may often result in a longer hospital stay and increased overall healthcare costs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20727708','lexi-content-ref-11755892','lexi-content-ref-25278772','lexi-content-ref-15221581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20727708','lexi-content-ref-11755892','lexi-content-ref-25278772','lexi-content-ref-15221581'])">Ref</a></span>). Opioid dose or route of administration does not appear to alter risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20100280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20100280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; mu-opioid receptor stimulation in the GI tract results in delayed gastric emptying, decreased peristalsis, decreased water and chloride secretion into the intestinal lumen, and slowed bowel motility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30788113','lexi-content-ref-15153834','lexi-content-ref-11755892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30788113','lexi-content-ref-15153834','lexi-content-ref-11755892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; changes in peristalsis may occur 5 to 25 minutes after administration of opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15153834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15153834'])">Ref</a></span>). However, OIC is defined based on a 7-day period of change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30778756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased dosing frequency (ie, daily vs 2 to 3 times per week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28034973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28034973'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic opioid administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28034973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28034973'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other medications that cause constipation</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opioid-induced neurotoxicity is an opioid-related adverse drug reaction more commonly associated with opioids that have active metabolites (eg, codeine, hydromorphone, meperidine, morphine, oxycodone). Symptoms may include allodynia, delirium, hallucinations, hyperalgesia, hypersomnolence, myoclonus, tremor, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; hypothesized to result from an accumulation of neuroexcitatory opioid metabolites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9514554','lexi-content-ref-19567715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9514554','lexi-content-ref-19567715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High opioid dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418392'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418392'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418392'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418392'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35418392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35418392'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, or fatal opioid-induced <b>respiratory depression</b> (OIRD) may occur with use of oxycodone in adult and pediatric patients. Effects include hypoventilation, hypoxia, hypercapnia, and respiratory acidosis, as well as reduced ventilatory responses to hypoxia and hypercapnia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35965031','lexi-content-ref-18456641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35965031','lexi-content-ref-18456641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; stimulation of mu-opioid receptors in the brainstem leads to suppression of the respiratory control network and depression of normal hypoxic and hypercapnic ventilatory responses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30915997','lexi-content-ref-20712805','lexi-content-ref-35965031','lexi-content-ref-18456641','lexi-content-ref-35189729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30915997','lexi-content-ref-20712805','lexi-content-ref-35965031','lexi-content-ref-18456641','lexi-content-ref-35189729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; OIRD reported within 2 hours after administration of oxycodone IR capsule (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36744649','lexi-content-ref-29029015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36744649','lexi-content-ref-29029015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses of intraoperative opioids (eg, morphine-equivalent daily dose ~40 mg in opioid-naïve patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552274'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Initiation of therapy or dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid naïve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid misuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28646524']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28646524'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute overdose</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of benzodiazepines, alcohol, or other CNS depressants</p>
<p style="text-indent:-2em;margin-left:6em;">• Postoperative patients with comorbid cardiac or respiratory disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552274','lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552274','lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sleep disorder (eg, obstructive sleep apnea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552274','lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552274','lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic pulmonary disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Cachexia</p>
<p style="text-indent:-2em;margin-left:6em;">• Debilitation</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abruptly stopping or reducing opioid use in patients with physical dependence on opioids can precipitate opioid-induced withdrawal (OIW) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668','lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668','lexi-content-ref-30701615'])">Ref</a></span>). Physical symptoms may include nausea, vomiting, diarrhea, abdominal cramps, tachycardia, chills, muscle aches, bone pain, agitation, anxiety, and insomnia. Psychosis has also been reported in case reports and case series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34286498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34286498'])">Ref</a></span>). The presence and severity of withdrawal symptoms are associated with an increased risk of nonfatal overdose and receptive syringe sharing in people who inject drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>). Avoidance of withdrawal symptoms may drive continued opioid use (Kosten 2019). Symptoms typically dissipate over 4 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Withdrawal; opioids bind to mu-opioid receptors on neurons in the locus coeruleus (LC) of the brainstem, causing decreased norepinephrine (NE) release. Upon abrupt discontinuation, the absence of opioid stimulation causes LC hyperactivity, excessive NE release, and subsequent autonomic hyperactivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; symptoms typically occur within 12 hours of discontinuation and peak at 36 to 72 hours; varies based on half-life of opioid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher cumulative dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35119438','lexi-content-ref-28866754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35119438','lexi-content-ref-28866754'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged exposure to opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20403936','lexi-content-ref-30701615','lexi-content-ref-35930693','lexi-content-ref-28866754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20403936','lexi-content-ref-30701615','lexi-content-ref-35930693','lexi-content-ref-28866754'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Initiation of mixed agonist/antagonist or partial agonist analgesics (eg, buprenorphine, butorphanol, nalbuphine, pentazocine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36704210','lexi-content-ref-35623179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36704210','lexi-content-ref-35623179'])">Ref</a></span>) in patients currently or recently taking full mu-opioid agonists may cause precipitated opioid withdrawal. (Precipitated withdrawal is similar to OIW, but with a faster onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22514846','lexi-content-ref-33818748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22514846','lexi-content-ref-33818748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation or dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of benzodiazepines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35930693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35930693'])">Ref</a></span>) or antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28866754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28866754'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;6 years, especially infants &lt;6 months of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20403936','lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20403936','lexi-content-ref-35119438'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35119438'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Critical illness involving CNS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35119438'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F204871"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions for the immediate release (IR) product reported in adults and in adolescents and adults for the extended release (ER) product unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (ER: 3% to 13%; IR: ≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (ER: 5% to 23%; IR: ≥3%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span>, nausea (ER: 11% to 23%; IR: ≥3%), vomiting (ER: 4% to 21%; IR: ≥3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Oxycodone: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxycodone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxycodone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe chronic lower back pain</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">193</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">196</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">191</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (ER: 2% to 13%; IR: ≥3%), drowsiness (ER [adults]: 9% to 23%; ER [adolescents]: 1% to 5%; IR: ≥3%), headache (ER: 14%; IR: ≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (ER: 1% to 11%; IR: ≥3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis (IR: &lt;3%), edema (≤5%), flushing (ER [adults]: 1% to 5%), heart failure (IR: &lt;3%), hypertension (ER [adults]: 1% to 5%), hypotension (IR: &lt;3%), orthostatic hypotension (ER: 1% to 5%), palpitations (IR: &lt;3%), peripheral edema (&lt;3%), tachycardia (≤5%), thrombophlebitis (IR: &lt;3%), vasodilation (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤5%), excoriation of skin (ER [adults]: 1% to 5%), hyperhidrosis (≤5%), skin photosensitivity (IR: &lt;3%), skin rash (≤5%), urticaria (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (≤5%), hypochloremia<b> (</b>ER [adolescents]: 1% to 5%), hyponatremia (ER [adolescents]: 1% to 5%), weight loss (ER [adolescents]: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤5%, including upper abdominal pain), anorexia (≤5%), decreased appetite (≤5%), diarrhea (≤6%), dyspepsia (≤5%), dysphagia (&lt;3%), gastritis (ER: 1% to 5%), gastroesophageal reflux disease (ER: 1% to 5%), gingivitis (IR: &lt;3%), glossitis (IR: &lt;3%), hiccups (ER: 1% to 5%), xerostomia (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (ER [adolescents]: 1% to 5%; ER [adults]: &lt;1%), urinary retention (ER [adolescents]: 1% to 5%; ER [adults]: &lt;1%), urinary tract infection (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (IR: &lt;3%, including iron deficiency anemia), decreased platelet count (ER [adolescents]: 1% to 5%), decreased red blood cells (ER [adolescents]: 1% to 5%), febrile neutropenia (ER [adolescents]: 1% to 5%), hemorrhage (IR: &lt;3%), leukopenia (IR: &lt;3%), neutropenia (ER [adolescents]: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (ER [adolescents]: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (IR: &lt;3%), infection (IR: &lt;3%), sepsis (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (ER: ≤5%), agitation (≤5%), anxiety (≤5%), asthenia (1% to 6%), changes in thinking (ER: 1% to 5%), chills (≤5%), confusion (≤5%), depression (ER [adolescents]: 1% to 5%; ER [adults]: &lt;1%), dysphoria (ER: 1% to 5%), euphoria (ER: ≤5%), fatigue (ER: 1% to 5%), hypertonia (IR: &lt;3%), hypoesthesia (≤5%), insomnia (ER: 1% to 5%; IR: ≥3%), irritability (ER [adults]: 1% to 5%), lethargy (ER: 1% to 5%), migraine (adults: ≤5%), nervousness (≤5%), neuralgia (IR: &lt;3%), paresthesia (ER [adolescents]: 1% to 5%; ER [adults]: &lt;1%), personality disorder (IR: &lt;3%), tremor (adults: ≤5%), twitching (ER: 1% to 5%), withdrawal syndrome (ER [adults]: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (adults: ≤5%), arthritis (IR: &lt;3%), back pain (adults: ≤5%), gout (IR: &lt;3%), laryngospasm (IR: &lt;3%), limb pain (ER [adolescents]: 1% to 5%), musculoskeletal pain (ER: ≤5%), myalgia (≤5%), neck pain (IR: &lt;3%), ostealgia (IR: &lt;3%), pathological fracture (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (IR: &lt;3%), blurred vision (ER [adults]: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (IR: &lt;3%), cough (adults: ≤5%), dyspnea (≤5%), epistaxis (IR: &lt;3%), flu-like symptoms (IR: &lt;3%), laryngismus (IR: &lt;3%), oropharyngeal pain (ER: 1% to 5%), oxygen saturation decreased (ER [adolescents]: 1% to 5%), pharyngitis (IR: &lt;3%), rhinitis (IR: &lt;3%), sinusitis (IR: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (&lt;3%), seroma (ER [adolescents]: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1% (any formulation or population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, depression of ST segment on ECG, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, night sweats, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, eructation, flatulence, increased appetite, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, hematuria, polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, amnesia, depersonalization, emotional lability, hallucination, hypotonia, malaise, memory impairment, restlessness, sleep disturbance, speech disturbance, stupor, vertigo, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any formulation or population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Circulatory depression, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation or population):</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, SIADH</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis, dental caries, diverticulitis of the gastrointestinal tract (exacerbation), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypogonadism</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, allodynia (opioid-induced hyperalgesia) (FDA Safety Communication 2023), drug abuse, drug dependence, hyperalgesia, mood changes, neonatal withdrawal, seizure, suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngeal edema</p></div>
<div class="block coi drugH1Div" id="F204887"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema) to oxycodone or any component of the formulation; significant respiratory depression; hypercapnia; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to other opioids; suspected surgical abdomen (eg, acute appendicitis or pancreatitis); any disease/condition that affects bowel transit; mild pain that can be managed with other pain medications (immediate release, suppository); mild, intermittent or short duration pain that can be managed with other pain medications or acute pain (extended release); chronic obstructive airway; status asthmaticus; cor pulmonale; acute alcoholism; delirium tremens; convulsive disorders; severe CNS depression; increased cerebrospinal or intracranial pressure; head injury; monoamine oxidase (MAO) inhibitors (concomitant use or within 14 days of therapy); pregnant women or during labor and delivery; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F204868"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxymorphone).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. Patients and caregivers should be educated on how to recognize respiratory depression and the importance of getting emergency assistance immediately (eg, calling 911) in the event of known or suspected overdose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Use with caution in patients with adrenocortical insufficiency, including Addison disease; dose adjustment may be required. Long-term opioid use may cause secondary hypogonadism, which may lead to mood disorders and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delirium tremens: Use with caution in patients with delirium tremens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; oxycodone clearance may decrease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to potential increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use with caution in patients who are morbidly obese.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture; dose adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use with caution in patients with toxic psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; oxycodone clearance may decrease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and CNS depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and CNS depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]). Consider the use of alternative nonopioid analgesics in these patients when possible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extended-release tablets: Tablets may be difficult to swallow and could become lodged in throat; patients with swallowing difficulties may be at increased risk. Cases of intestinal obstruction or diverticulitis exacerbation have also been reported, including cases requiring medical intervention to remove the tablet; patients with an underlying GI disease (eg, esophageal cancer, colon cancer) may be at increased risk.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: Use with caution in patients with a history of substance abuse disorder; potential for drug dependency exists. Other factors associated with increased risk for misuse include concomitant depression or other mental health conditions, higher opioid dosages, or taking other CNS depressants. Consider offering naloxone prescriptions in patients with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (≥50 morphine milligram equivalents [MME]/day orally), concomitant benzodiazepine use, and patients at risk for returning to a high dose after losing tolerance (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Outpatient setting: Opioids should not be used as first-line therapy for acute (&lt;1-month duration), subacute (1- to 3-month duration), or chronic pain (&gt;3-month duration [outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-based opioid use disorder treatment]). Preferred management includes nonpharmacologic therapy and non-opioid therapy (eg, nonsteroidal anti-inflammatory drugs, acetaminophen, certain antiseizure medications and antidepressants) as appropriate for the specific condition. If opioid therapy is initiated, it should be combined with nonpharmacologic and non-opioid therapy, as appropriate. Prior to initiation, known risks and realistic benefits of opioid therapy should be discussed with the patient. Therapy should be initiated at the lowest effective dosage using IR opioids (instead of ER/long-acting opioids). For the treatment of acute pain, therapy should only be given for the expected duration of pain severe enough to require opioids and prescribed as needed (not scheduled). For the treatment of subacute and chronic pain, realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Risk to patients increases with higher opioid dosages. Dosages ≥50 MME/day are likely to not have increased benefit to pain relief or function relative to overall risk to patients; before increasing dosage to ≥50 MME/day, readdress pain and reassess evidence of individual benefits and risks (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.</p>
<p style="text-indent:-2em;margin-left:4em;">• Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: To ensure that the benefits of opioid analgesics outweigh the risks of substance use disorder, abuse, and misuse, a REMS is required. Drug companies with approved opioid analgesic products must make REMS-compliant education programs available to health care providers. Health care providers are encouraged to complete a REMS-compliant education program; counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products; emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist; and consider other tools to improve patient, household, and community safety.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postoperative patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p></div>
<div class="block dosfc drugH1Div" id="F46945076"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Xtampza ER: Strength is expressed in terms of oxycodone base.</p>
<p style="text-indent:-2em;margin-left:4em;">9 mg equivalent to 10 mg oxycodone hydrochloride</p>
<p style="text-indent:-2em;margin-left:4em;">13.5 mg equivalent to 15 mg oxycodone hydrochloride</p>
<p style="text-indent:-2em;margin-left:4em;">18 mg equivalent to 20 mg oxycodone hydrochloride</p>
<p style="text-indent:-2em;margin-left:4em;">27 mg equivalent to 30 mg oxycodone hydrochloride</p>
<p style="text-indent:-2em;margin-left:4em;">36 mg equivalent to 40 mg oxycodone hydrochloride</p></div>
<div class="block foc drugH1Div" id="F204880"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule ER 12 Hour Abuse-Deterrent, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xtampza ER: 9 mg (100 ea); 13.5 mg (100 ea); 18 mg (100 ea); 27 mg (100 ea); 36 mg (100 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (5 mL, 15 mL, 473 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxaydo: 5 mg, 7.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roxicodone: 5 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roxicodone: 15 mg [scored; contains fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roxicodone: 30 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Abuse-Deterrent, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RoxyBond: 15 mg, 30 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Abuse-Deterrent, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RoxyBond: 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet ER 12 Hour Abuse-Deterrent, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">OxyCONTIN: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">OxyCONTIN: 80 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 15 mg [DSC], 20 mg, 30 mg [DSC], 40 mg, 60 mg [DSC], 80 mg</p></div>
<div class="block geq drugH1Div" id="F204864"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F5989443"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 12 Hour Abuse-Deterrent</b> (Xtampza ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 mg (per each): $7.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13.5 mg (per each): $11.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $14.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27 mg (per each): $19.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36 mg (per each): $24.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (oxyCODONE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (oxyCODONE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $5.60 - $12.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (oxyCODONE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $1.05 - $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Abuse-Deterrent</b> (RoxyBond Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $15.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $18.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $25.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet ER 12 Hour Abuse-Deterrent</b> (oxyCODONE HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4.23 - $5.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $7.88 - $9.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $13.10 - $16.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $28.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet ER 12 Hour Abuse-Deterrent</b> (OxyCONTIN Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $6.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $9.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $12.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $17.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $20.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $29.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $36.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Oxaydo Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $12.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $19.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (oxyCODONE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.08 - $0.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.15 - $1.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.12 - $2.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.27 - $2.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.18 - $4.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Roxicodone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $6.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $12.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867797"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Supeudol 10: 10 mg (12 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Supeudol 20: 20 mg (12 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxy-IR: 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Supeudol: 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet ER 12 Hour Abuse-Deterrent, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">OxyNEO: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">OxyNEO: 80 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</p></div>
<div class="block csi drugH1Div" id="F204937"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block adm drugH1Div" id="F204884"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Appropriate laxatives should be administered to avoid the constipating side effects associated with use. Antiemetics may be needed for persistent nausea. Some dosage forms (eg, ER) may not be appropriate for administration through feeding tubes (eg, gastric, NG). Refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>ER dosage forms:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Tablet: Administer with or without food. Swallow tablet whole. Do not moisten, dissolve, cut, crush, break, or chew extended release tablets. Extended release tablets should be administered one at a time and each followed with water immediately after placing in the mouth.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Administer each dose with food and approximately the same amount. For patients with difficulty swallowing, capsule may be opened and the contents sprinkled on soft foods (eg, applesauce, pudding, yogurt, ice cream, jam) or into a cup for administration directly into the mouth. Rinse mouth immediately afterwards to ensure all contents have been swallowed. Contents of capsule may also be administered through a nasogastric (NG) tube or gastrostomy tube (G-tube). Flush tube with water first, then pour capsule contents directly into tube (do not premix capsule contents with fluid that will be used to flush them through the tube). After contents have been placed in tube, flush tube with 15 mL of water, milk, or liquid nutritional supplement once and then repeat twice with 10 mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Tablet, abuse deterrent and extended or controlled release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Roxybond (oxycodone) tablets are formulated to have increased resistance to cutting, crushing, grinding, or breaking. Pharmacokinetics are similar to other IR oxycodone formulations. Nonabuse-deterrent IR tablet, capsule, and oral solution formulations are available. Oxycodone ER capsule contents may be taken by sprinkling the contents onto soft food (ie, applesauce, ice cream, yogurt). If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, clinicians should be advised that oral morphine has been shown to have significantly increased C<sub>max</sub> and decreased T<sub>max</sub> in the immediate (1 to 2 weeks) and long-term (6-months) period after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IR dosage forms:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution: Administer with or without food. Available in two strengths; 1 mg/mL and a concentrated oral solution (20 mg/mL). Precautions should be taken to avoid confusion between the different concentrations; prescriptions should have the concentration specified as well as the dose clearly represented as milligram (mg) of oxycodone, not volume (mL). The enclosed calibrated oral syringe should always be used to administer the concentrated oral solution to ensure the dose is measured and administered accurately. The concentrated oral solution (20 mg/mL) may be used in opioid-tolerant patients (taking ≥30 mg/day of oxycodone or equivalent for ≥1 week); may also be used in palliative care patients who have difficulty and/or are unable to swallow. The concentrate is not substantially absorbed sublingually/orally and requires the GI tract for effective absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2458208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2458208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Without abuse deterrent:</i> Administer with or without food. When administered with food, onset may be delayed.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>With abuse deterrent:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Oxaydo</i>: Administer with or without food. Do not crush, chew, or dissolve the tablets. Due to inactive ingredient that causes nasal burning (upon snorting) and throat irritation, the tablet must be swallowed whole with enough water to ensure complete swallowing immediately after placing in the mouth. The tablet should not be wet prior to placing in the mouth.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Suppository [Canadian product]: Administer rectally. Do not break, crush, cut, or dissolve the suppositories.</p></div>
<div class="block admp drugH1Div" id="F52613495"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release (capsule, oral solution, tablets): May administer with food to decrease GI upset:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Available in 2 strengths: 1 mg/mL and a concentrated oral solution (20 mg/mL). Precautions should be taken to avoid confusion between the different concentrations; prescriptions should have the concentration specified as well as the dose clearly represented as milligram (mg) of oxycodone, not volume (mL). The enclosed calibrated oral syringe should always be used to administer the concentrated oral solution to ensure the dose is measured and administered accurately. The concentrated oral solution (20 mg/mL) should only be used in opioid-tolerant patients (taking ≥30 mg/day of oxycodone or equivalent for ≥1 week).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (Oxaydo): Swallow whole with adequate water to ensure complete swallowing immediately after placing in the mouth; the formulation uses technology designed to discourage common methods of tampering to prevent misuse/abuse. The tablet should not be wet prior to placing in the mouth. Do not crush, chew, or dissolve nor administer via feeding tubes (eg, gastric, NG) due to potential for obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Tablet (eg, OxyContin): May administer with food to decrease GI upset. Swallow whole; do not moisten, dissolve, cut, crush, chew, or break as this would result in rapid release of oxycodone and absorption of a potentially fatal dose of drug. Administer one at a time and follow each with water immediately after placing in the mouth. For oral use only; do not administer rectally; increased risk of adverse events due to better rectal absorption.</p></div>
<div class="block meg drugH1Div" id="F10162706"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Oxaydo: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F202080s012lbl.pdf%23page%3D30&amp;token=B%2FoglC%2Ba8O17ZofewETV1hSh%2Bkc9vAZTV%2B%2FJId24gOlEVNJWJzjxKex30IlCk3qZwxFrkRzFJZYnQcPKdRNlqrXL1MnGVsHKpmYwLGoYowNe8zWhVSPSBEQIO2tie3%2B1&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202080s012lbl.pdf#page=30</a></p>
<p style="text-indent:-2em;margin-left:4em;">Oxycodone hydrochloride capsules: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F200534s013lbl.pdf%23page%3D32&amp;token=hCdFCOZ%2FvgUVnw4p1tLu%2F7t%2BV6G7M%2FItvDqEGaOqWSTFHvRQURLuNmvBIhEMv7haey8GkVjhsi4rK19WDav8iuSH8K6WVk76wUAyXblD40puqTwRdxFG%2B1seLfhSWd%2FG&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/200534s013lbl.pdf#page=32</a></p>
<p style="text-indent:-2em;margin-left:4em;">Oxycodone hydrochloride oral solution: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F201194s009lbl.pdf%23page%3D33&amp;token=Fnpxez3wkfTirxID6AC1fRoA%2FhFjhDF5%2B5SPamiTCZ8EKdMlzhJgmDY%2FTtG2O%2BL52o9vXGXZm25yNv6DezcdCjC%2B2ewT4PpGBL%2FQS%2BbySjufhVdV7M74KJeaBP%2FuZPh3&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/201194s009lbl.pdf#page=33</a></p>
<p style="text-indent:-2em;margin-left:4em;">OxyContin: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022272s048lbl.pdf%23page%3D49&amp;token=cKUW9%2FS57pws16tl7V4NHjbfDYYfQHjzt9ykptNMt75l4cXpdOjcoLvWjKyBuNRZtD8JQFL3P32toQojJf2TJ9YoyWuC9Ej2DVqbKbtN%2F122UbffKOZ3MOBhe59a%2BGuN&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022272s048lbl.pdf#page=49</a></p>
<p style="text-indent:-2em;margin-left:4em;">Roxybond: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F209777s007lbl.pdf%23page%3D39&amp;token=GNwr3MyA0yKaPIYQ9%2BQCdwC0f7nkVoD1s7PNCBrXRa2frfRHJopEy4kmeIm1ReGCozF%2FgrsECJaUZavD%2B0Q6egva1e87q7SuXFK5AV4WcU6Nfm8P76SDDU19%2Fqkb6bYR&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209777s007lbl.pdf#page=39</a></p>
<p style="text-indent:-2em;margin-left:4em;">Roxicodone: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021011s013lbl.pdf%23page%3D30&amp;token=Cc9LaeWQJepiIvP%2FaRCM6D4y9h%2BEsygzta2vmcaOHsuS%2FJGayXdZlp2YQyK%2FWnebB%2FTl94yaB9ouAIMHy38qyIFXrdwdhzONAudLwHWDLW1d36rfwL4eYAFLu%2F8joO56&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021011s013lbl.pdf#page=30</a></p>
<p style="text-indent:-2em;margin-left:4em;">Xtampza ER: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F208090s015lbl.pdf%23page%3D39&amp;token=mD0ybMLHKLOBdeK4OoCU70Qlq07suGXAfBSba%2FERAmOSbNqnqTQVajJDnPokwNqcqYjggKYzCwq2rh0zI835qNHxrHf3ahhY8gU%2Bn7zuob0ITMTD%2Fg4WdqV2IwaJ%2Bel5&amp;TOPIC_ID=9729" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208090s015lbl.pdf#page=39</a></p></div>
<div class="block use drugH1Div" id="F204883"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Pain management:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Immediate release:</b> Management of acute or chronic moderate to severe pain when the use of an opioid analgesic is appropriate and for which alternative treatments are inadequate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extended release:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules (Xtampza ER): Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets (Oxycontin): Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in adults and opioid-tolerant pediatric patients ≥11 years of age who are already receiving and tolerating a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent.</p></div>
<div class="block mst drugH1Div" id="F204943"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">OxyCODONE may be confused with HYDROcodone, oxyBUTYnin, OxyCONTIN, oxyMORphone</p>
<p style="text-indent:-2em;margin-left:4em;">OxyCONTIN may be confused with MS Contin, oxyBUTYnin, oxyCODONE, oxyMORphone, oxytocin</p>
<p style="text-indent:-2em;margin-left:4em;">OxyFast may be confused with Roxanol</p>
<p style="text-indent:-2em;margin-left:4em;">Roxicodone may be confused with Roxanol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F204929"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F204873"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of OxyCODONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of OxyCODONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: OxyCODONE may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: Use of oxycodone is not recommended for patients taking MAOIs or within 14 days of MAOI discontinuation. If combined, use test doses and frequent titration of small doses while monitoring blood pressure, CNS depression, and signs of serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4).  Management: If concomitant use of opioid agonists that are metabolized by CYP3A4 and nefazodone is necessary, consider dose reduction of the opioid until stable drug effects are achieved. Monitor for increased opioid effects and serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May enhance the CNS depressant effect of OxyCODONE. PHENobarbital may decrease the serum concentration of OxyCODONE. Management: Avoid use of oxycodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased oxycodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the CNS depressant effect of OxyCODONE. Primidone may decrease the serum concentration of OxyCODONE. Management: Avoid use of oxycodone and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased oxycodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308594"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Chronic opioid use may cause hypogonadism and hyperprolactinemia which may decrease fertility in patients of reproductive potential. Menstrual cycle disorders (including amenorrhea), erectile dysfunction, and impotence have been reported. The incidence of hypogonadism may be increased with the use of opioids in high doses or long-acting opioid formulations. It is not known if the effects on fertility are reversible. Monitor patients on long-term therapy (de Vries 2020; Gadelha 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Consider family planning, contraception, and the effects on fertility prior to prescribing opioids for chronic pain to patients who could become pregnant (ACOG 2017; CDC [Dowell 2022]).</p></div>
<div class="block pri drugH1Div" id="F204890"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Oxycodone crosses the placenta (Kokki 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of opioids may be associated with poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2022]). Opioids used as part of obstetric analgesia/anesthesia during labor and delivery may temporarily affect the fetal heart rate (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Neonatal abstinence syndrome (NAS)/neonatal opioid withdrawal syndrome (NOWS) may occur following prolonged in utero exposure to opioids (CDC [Dowell 2022]). NAS/NOWS may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. Presentation of symptoms varies by opioid characteristics (eg, immediate release, sustained release), time of last dose prior to delivery, drug metabolism (maternal, placental, and infant), net placental transfer, as well as other factors (AAP [Hudak 2012]; AAP [Patrick 2020]). Clinical signs characteristic of withdrawal following in utero opioid exposure include excessive crying or easily irritable, fragmented sleep (&lt;2 to 3 hours after feeding), tremors, increased muscle tone, or GI dysfunction (hyperphagia, poor feeding, feeding intolerance, watery or loose stools) (Jilani 2022). NAS/NOWS occurs following chronic opioid exposure and would not be expected following the use of opioids at delivery (AAP [Patrick 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor infants of mothers on long-term/chronic opioid therapy for symptoms of withdrawal. Symptom onset reflects the half-life of the opioid used. Monitor infants for at least 3 days following exposure to immediate-release opioids; monitor for at least 4 to 7 days following exposure to sustained-release opioids (AAP [Patrick 2020]; CDC [Dowell 2022]). Monitor newborns for excess sedation and respiratory depression when opioids are used during labor.</p>
<p style="text-indent:0em;margin-top:2em;">When opioids are needed to treat acute pain in pregnant patients, the lowest effective dose for only the expected duration of pain should be prescribed (CDC [Dowell 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Opioid use for pain following vaginal or cesarean delivery should be made as part of a shared decision-making process. A stepwise, multimodal approach to managing postpartum pain is recommended. A low-dose, low-potency, short-acting opioid such as oxycodone can be used to treat acute pain associated with delivery when needed (ACOG 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Opioids are not preferred for the treatment of chronic noncancer pain during pregnancy; consider strategies to minimize or avoid opioid use. Advise pregnant patients requiring long-term opioid use of the risk of NAS/NOWS and provide appropriate treatment for the neonate after delivery. NAS/NOWS is an expected and treatable condition following chronic opioid use during pregnancy and should not be the only reason to avoid treating pain with an opioid in pregnant patients (ACOG 2017; CDC [Dowell 2022]). Do not abruptly discontinue opioids during pregnancy; taper prior to discontinuation when appropriate, considering the risks to the pregnant patient and fetus if maternal withdrawal occurs (CDC [Dowell 2022]).</p></div>
<div class="block brc drugH1Div" id="F11347295"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Oxycodone is present in breast milk in variable concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">In one study, oxycodone was measurable in breast milk up to 37 hours after the last maternal dose and therapeutic concentrations were detected in the serum of a breastfeeding infant (Seaton 2007). Oxycodone was also detected in the urine of a breastfed infant (Sulton-Villavasso 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">CNS depression, constipation, decreased feeding, and respiratory distress/irregular breathing have been observed in infants exposed to oxycodone via breast milk (Lam 2012; Sulton-Villavasso 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Nonopioid analgesics are preferred for lactating patients who require pain control peripartum or for surgery outside of the postpartum period. When opioids are needed for lactating patients, use the lowest effective dose for the shortest duration of time to limit adverse events in the mother and breastfeeding infant (AAP [Sachs 2013]; ABM [Martin 2018]; ABM [Reece-Stremtan 2017]). When an opiate is needed, use of oxycodone in breastfeeding patients is not recommended by some guidelines (AAP [Sachs 2013]). Other guidelines note prolonged and frequent use may cause neonatal sedation (ABM [Martin 2018]). Maternal doses greater than 30 mg/day are not recommended (ABM [Martin 2018]; ACOG 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">When chronic opioids are prescribed prenatally and continued postpartum, breastfeeding may be initiated to help mitigate potential newborn withdrawal; monitor both the mother and the infant (AAP [Meek 2022]; AAP [Patrick 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor infants exposed to opioids via breast milk for drowsiness, sedation, feeding difficulties, or limpness (ACOG 2019). Withdrawal symptoms may occur when maternal use is discontinued, or breastfeeding is stopped.</p></div>
<div class="block dic drugH1Div" id="F204891"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Instruct patient to avoid high-fat meals when taking some products (food has no effect on the reformulated OxyContin).</p></div>
<div class="block mop drugH1Div" id="F204877"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Pain relief, respiratory and mental status, blood pressure; bowel function; signs/symptoms of misuse, abuse, and substance use disorder; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Alternate recommendations:</b> Subacute or chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-based opioid use disorder treatment):</i> Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. In patients with subacute pain initially treated for acute pain, reassess pain and function after 30 days to address potentially reversible causes of pain and prevent unintentional long-term opioid therapy. In patients on long-term therapy, re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Toxicology testing is recommended prior to initiation and at least yearly (includes controlled prescription medications, illicit drugs of abuse, and benzodiazepines). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (CDC [Dowell 2022]).</p></div>
<div class="block pha drugH1Div" id="F204867"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression</p></div>
<div class="block phk drugH1Div" id="F204886"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Pain relief: Immediate release: 10 to 15 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Immediate release: 0.5 to 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Immediate release: 3 to 6 hours; Extended release: ≤12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Children 2 to 10 years: 2.1 L/kg (range: 1.2 to 3.7 L/kg); Adults: 2.6 L/kg; distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 38% to 45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatically via CYP3A4 to noroxycodone (has weak analgesic activity), noroxymorphone, and alpha- and beta-noroxycodol. CYP2D6 mediated metabolism produces oxymorphone (has analgesic activity; low plasma concentrations [&lt;15%]), alpha- and beta-oxymorphol.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Extended release tablet, immediate release: 60% to 87%; Extended release capsule is not bioequivalent to extended release tablet; however AUC, is similar in a fed state.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life:</p>
<p style="text-indent:-2em;margin-left:4em;">Apparent: Immediate release: 3.2 to ~4 hours; Extended release tablet: 4.5 hours; Extended release capsule: 5.6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Elimination: Children 2 to 10 years: 1.8 hours (range: 1.2 to 3 hours); Adults: 3.7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with CrCl &lt;60 mL/minute: Half-life increases by 1 hour, but peak oxycodone concentrations increase by 50% and AUC increases by 60%.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with mild to moderate hepatic impairment: Half-life increases by 2.3 hours, peak oxycodone concentrations increase by 50%, and AUC increases by 95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Immediate release: 1.2 to 1.9 hours; Extended release: 4 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: (~10% as parent; ~65% as metabolites [noroxycodone (23%, active), oxymorphone (10%, active), noroxymorphone (14%, weakly active), reduced metabolites (≤18%)]) (Kinnunen 2019).</p></div>
<div class="block phksp drugH1Div" id="F51160078"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Higher peak plasma oxycodone (50%), and noroxycodone (20%), higher AUC for oxycodone (60%), noroxycodone (50%), and oxymorphone (40%) in patients with CrCl &lt;60 mL/minute. There is an increased half-life elimination for oxycodone elimination of only 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Peak plasma oxycodone and noroxycodone concentrations 50% and 20% higher; AUC values are 95% and 65% higher, respectively, in mild to moderate hepatic impairment. Oxymorphone peak plasma concentration and AUC values are lower by 30% and 40%. The half-life elimination for oxycodone is increased by 2.3 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F204892"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Oxycodon accord | Oxycodon hcl ratiopharm | Oxycontin | Oxygerolan | Oxynorm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Genrx oxycodone mr | Gxp oxycodone | Novacodone | Oxycodone actavis | Oxycodone as | Oxycodone bnm | Oxycodone genpar | Oxycodone gppl | Oxycodone gx | Oxycodone medis | Oxycodone neo health | Oxycodone nhpl | Oxycodone sandoz | Oxycodone wt | Oxycodone zp | Oxycodor | Oxycontin | Oxylenus | Oxyndone | Oxynorm | Proladone | Xedone</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Oxycodon sandoz | Oxycontin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone | Oxycodone actavis | Oxylan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de oxicodona | Oxycontin | Oxygesic | Oxypynal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Oxycodon actavis | Oxycodon sandoz | Oxycodon streuli | Oxycodone mepha retard | Oxynorm | Unox</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nokotin | Oxycontin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Oxicodona clorhidrato | Oxycontin | Oxycontin orf</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dolocodon | Oxycodon ratiopharm | Oxykodon | Oxykodon actavis | Oxykodon G. L. Pharma | Oxykodon stada</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Carenoxal | Oxycan uno | Oxycodon Hcl AbZ | Oxycodon HCl Actavis | Oxycodon Hcl AL | Oxycodon hcl awd | Oxycodon HCl beta | Oxycodon HCl CT | Oxycodon hcl dura | Oxycodon hcl hexal | Oxycodon HCL Hormosan | Oxycodon HCl Krugmann | Oxycodon HCl Krugmann akut | Oxycodon hcl mylan | Oxycodon hcl ratiopharm | Oxycodon hcl sandoz | Oxycodon hcl stada | Oxycodon hcl winthrop | Oxycodon hcl zentiva | Oxycodon painbreak | Oxycodone hcl acino | Oxycodone hcl aristo | Oxycodonhydrochlorid 1 A Pharma | Oxycodonhydrochlorid axcount | Oxycodonhydrochlorid Hennig | Oxycodonhydrochlorid Heumann | Oxycodonhydrochlorid puren | Oxyconoica | Oxygesic | Oxygesic akut | Oxynorm</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dolocodon | Oxycodone vitabalans</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Oxynorm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Oxicodona aristo | Oxicodona kern pharma | Oxicodona Sandoz | Oxynorm</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Oxycodon Hcl Accord | Oxycodone orion | Oxycodone Ratiopharm | Oxycodone sandoz | Oxycodone stada | Oxycodone vitabalans | Oxycorion depot | Oxynorm | Oxyratio</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone accord LP | Oxycodone arrow | Oxycodone biogaran LP | Oxycodone Eg | Oxycodone mylan | Oxycodone sandoz | Oxycontin lp | Oxynorm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Carexil | Dolocodon | Ixyldone | Leveraxo | Longtec | Lynlor | Onexila XL | Oxeltra | Oxycodone | Oxycontin | Oxylan | Oxynorm | Oxypro | Proladone | Reltebon | Shortec | Zomestine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Codoxy | Codoxy rapid | Oxycodone vitabalans | Oxycontin | Reltebon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Oxyneo | Oxynorm</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dancex | Oxycodone | Oxycodone actavis | Oxycontin | Oxynorm | Reltebon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ossicodone aurobindo | Ossicodone Bruno Farmaceutici | Oxicodone accord | Oxicodone sandoz | Oxycontin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone | Oxycontin | Oxycontin dainippo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ocodone cr | Oxycontin | Oxycontin cr | Procontin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone vitabalans | Oxycontin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Oxycodon | Oxycodon actavis | Oxycodon Hcl Accord | Oxycodon hcl gl | Oxycodon hcl mundipharma | Oxycodon hcl pch | Oxycodon hcl ratiopharm | Oxycodon hcl sandoz | Oxycodon HCl Teva | Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone actavis | Oxycodone orifarm | Oxycodone vitabalans | Oxycontin | Oxynorm | Reltebon</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone sandoz | Oxycontin | Oxydone Bnm | Oxynorm</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Nokotin | Oxirapid | Oxycontin | Oxydonna</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone vitabalans | Oxydolor Fast | Xancodal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxycodone HCL | Oxycontin | Oxyir | Roxybond | Xtampza er</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Olbete</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Sedalgina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lynlor | OxyNorm</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Oxicodona Sandoz | Reltebon</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Oxynorm</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Enoxy Depot | Oxikodon acino | Oxikodon actavis | Oxikodon evolan | Oxycodone depot 1a farma | Oxycodone depot orion | Oxycodone g.l. | Oxycodone lannacher | Oxycodone orifarm | Oxycodone sandoz | Oxycodone teva | Oxycodone vitabalans | Oxyconta depot | Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Oksikodon vitabalans | Oxycontin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Contiroxil | Dolocodon | Oxycodone pr actavis | Oxypro</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Oxopane</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxynorm</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dolonica</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Oxynorm</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Oxycontin | Oxycorrell | Oxynorm</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30915997">
<a name="30915997"></a>Algera MH, Kamp J, van der Schrier R, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. <i>Br J Anaesth</i>. 2019;122(6):e168-e179. doi:10.1016/j.bja.2018.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30915997/pubmed" id="30915997" target="_blank">30915997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34412076">
<a name="34412076"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Obstetrics. Pharmacologic stepwise multimodal approach for postpartum pain management: ACOG clinical consensus no. 1. <i>Obstet Gynecol.</i> 2021;138(3):507-517. doi:10.1097/AOG.0000000000004517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/34412076/pubmed" id="34412076" target="_blank">34412076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742676">
<a name="28742676"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Obstetrics. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. <i>Obstet Gynecol</i>. 2017;130(2):e81-e94. doi:10.1097/AOG.0000000000002235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28742676/pubmed" id="28742676" target="_blank">28742676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society (APS). <i>Pain assessment and management initiative (PAMI)</i> dosing guide. Updated November 2016b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.2">
<a name="APS.2"></a>American Pain Society (APS). <i>Principles of analgesic use</i>. Seventh edition. 2016a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20403936">
<a name="20403936"></a>Anand KJ, Willson DF, Berger J, et al. Tolerance and withdrawal from prolonged opioid use in critically ill children. <i>Pediatrics</i>. 2010;125(5):e1208-e1225. doi:10.1542/peds.2009-0489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/20403936/pubmed" id="20403936" target="_blank">20403936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12422999">
<a name="12422999"></a>Anderson DT, Fritz KL, Muto JJ. Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases. <i>J Anal Toxicol</i>. 2002;26(7):448-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/12422999/pubmed" id="12422999" target="_blank">12422999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APO-Oxycodone.1">
<a name="APO-Oxycodone.1"></a>APO-Oxycodone CR (oxycodone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>Association of Paediatric Anaesthetists of Great Britain and Ireland (APA). Good practice in postoperative and procedural pain management, 2nd edition. <i>Paediatr Anaesth</i>. 2012;22(Suppl 1):1-79.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30254187">
<a name="30254187"></a>Azhar A, Kim YJ, Haider A, et al. Response to oral immediate-release opioids for breakthrough pain in patients with advanced cancer with adequately controlled background pain. <i>Oncologist</i>. 2019;24(1):125-131. doi:10.1634/theoncologist.2017-0583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30254187/pubmed" id="30254187" target="_blank">30254187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12362012">
<a name="12362012"></a>Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/12362012/pubmed" id="12362012" target="_blank">12362012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32199668">
<a name="32199668"></a>Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. <i>Drug Alcohol Depend</i>. 2020;211:107932. doi:10.1016/j.drugalcdep.2020.107932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/32199668/pubmed" id="32199668" target="_blank">32199668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi:10.1016/j.amjmed.2012.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buys.1">
<a name="Buys.1"></a>Buys MJ. Use of opioids for postoperative pain control. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carr.1">
<a name="Carr.1"></a>Carr D. Management of acute pain in the patient chronically using opioids for non-cancer pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carvalho.1">
<a name="Carvalho.1"></a>Carvalho B, Sutton CD. Post-cesarean delivery analgesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Common elements in guidelines for prescribing opioids for chronic pain. <a href="https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf" target="_blank">https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf</a>. Published 2015. Accessed September 13, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22514846">
<a name="22514846"></a>Center for Substance Abuse Treatment. <i>Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction</i>. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22514846/pubmed" id="22514846" target="_blank">22514846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20712805">
<a name="20712805"></a>Chang SH, Maney KM, Phillips JP, Langford RM, Mehta V. A comparison of the respiratory effects of oxycodone versus morphine: a randomised, double-blind, placebo-controlled investigation. <i>Anaesthesia</i>. 2010;65(10):1007-1012. doi:10.1111/j.1365-2044.2010.06498.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/20712805/pubmed" id="20712805" target="_blank">20712805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28226340">
<a name="28226340"></a>Cheung CW, Ching Wong SS, Qiu Q, Wang X. Oral oxycodone for acute postoperative pain: a review of clinical trials. <i>Pain Physician</i>. 2017;20(2S):SE33-SE52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28226340/pubmed" id="28226340" target="_blank">28226340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.1">
<a name="Cote.1"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30340754">
<a name="30340754"></a>Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. <i>Gastroenterology</i>. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30340754/pubmed" id="30340754" target="_blank">30340754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30833302">
<a name="30833302"></a>Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. <i>Clin J Am Soc Nephrol</i>. 2019;14(6):917-931. doi:10.2215/CJN.05180418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30833302/pubmed" id="30833302" target="_blank">30833302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33818748">
<a name="33818748"></a>De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. <i>Clin Drug Investig</i>. 2021;41(5):425-436. doi:10.1007/s40261-021-01032-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/33818748/pubmed" id="33818748" target="_blank">33818748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511863">
<a name="31511863"></a>de Vries F, Bruin M, Lobatto DJ, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab.</i> 2020;105(3):1020-1029. doi:10.1210/clinem/dgz022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/31511863/pubmed" id="31511863" target="_blank">31511863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21243342">
<a name="21243342"></a>Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol</i>. 2011; 67:865-867. doi:10.1007/s00228-011-0992-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/21243342/pubmed" id="21243342" target="_blank">21243342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26987082">
<a name="26987082"></a>Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/26987082/pubmed" id="26987082" target="_blank">26987082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327391">
<a name="36327391"></a>Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. <i>MMWR Recomm Rep</i>. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/36327391/pubmed" id="36327391" target="_blank">36327391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30788113">
<a name="30788113"></a>Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. <i>United European Gastroenterol J</i>. 2019;7(1):7-20. doi:10.1177/2050640618818305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30788113/pubmed" id="30788113" target="_blank">30788113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17330696">
<a name="17330696"></a>Foral PA, Ineck JR, Nystrom KK. Oxycodone accumulation in a hemodialysis patient. <i>South Med J</i>. 2007;100(2):212-214. doi:10.1097/01.smj.0000242876.45747.0a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/17330696/pubmed" id="17330696" target="_blank">17330696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28646524">
<a name="28646524"></a>Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. <i>Addiction</i>. 2018;113(1):59-66. doi:10.1111/add.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28646524/pubmed" id="28646524" target="_blank">28646524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35066756">
<a name="35066756"></a>Gadelha MR, Karavitaki N, Fudin J, Bettinger JJ, Raff H, Ben-Shlomo A. Opioids and pituitary function: expert opinion. <i>Pituitary</i>. 2022;25(1):52-63. doi:10.1007/s11102-021-01202-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35066756/pubmed" id="35066756" target="_blank">35066756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17244106">
<a name="17244106"></a>Gallagher RM, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. <i>Pain Med</i>. 2007;8(1):71-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/17244106/pubmed" id="17244106" target="_blank">17244106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35418392">
<a name="35418392"></a>Godwin B, Frank C, Molnar F, Dyks D, Akter R. Identification and management of opioid-induced neurotoxicity in older adults. <i>Can Fam Physician</i>. 2022;68(4):269-270. doi:10.46747/cfp.6804269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35418392/pubmed" id="35418392" target="_blank">35418392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30552274">
<a name="30552274"></a>Gupta K, Nagappa M, Prasad A, et al. Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses. <i>BMJ Open</i>. 2018;8(12):e024086. doi:10.1136/bmjopen-2018-024086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30552274/pubmed" id="30552274" target="_blank">30552274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36744649">
<a name="36744649"></a>Hellinga M, Algera MH, Olofsen E, et al. Oral oxycodone-induced respiratory depression during normocapnia and hypercapnia: A pharmacokinetic-pharmacodynamic modeling study. <i>Clin Pharmacol Ther</i>. 2023;113(5):1080-1088. doi:10.1002/cpt.2863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/36744649/pubmed" id="36744649" target="_blank">36744649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28267689">
<a name="28267689"></a>Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An educational intervention decreases opioid prescribing after general surgical operations. <i>Ann Surg</i>. 2018;267(3):468-472. doi:10.1097/SLA.0000000000002198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28267689/pubmed" id="28267689" target="_blank">28267689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20727708">
<a name="20727708"></a>Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. <i>J Pain Symptom Manage</i>. 2010;40(5):696-703. doi:10.1016/j.jpainsymman.2010.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/20727708/pubmed" id="20727708" target="_blank">20727708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC, Committee on Drugs, et al, "Neonatal Drug Withdrawal," <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34942181">
<a name="34942181"></a>Jilani SM, Jones HE, Grossman M, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. <i>J Pediatr.</i> 2022;243:33-39.e1. doi:10.1016/j.jpeds.2021.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/34942181/pubmed" id="34942181" target="_blank">34942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925318">
<a name="32925318"></a>Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: An international prospective, observational trial. <i>Anesth Analg</i>. 2020;131(4):1012-1024. doi:10.1213/ANE.0000000000004788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/32925318/pubmed" id="32925318" target="_blank">32925318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30652261">
<a name="30652261"></a>Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. <i>Clin Pharmacokinet</i>. 2019;58(6):705-725. doi:10.1007/s40262-018-00731-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30652261/pubmed" id="30652261" target="_blank">30652261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8695073">
<a name="8695073"></a>Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. <i>J Clin Anesth</i>. 1996;8(1):13-18. doi:10.1016/0952-8180(95)00092-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/8695073/pubmed" id="8695073" target="_blank">8695073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22448718">
<a name="22448718"></a>Kokki M, Franco MG, Raatikainen K, et al. Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. <i>Basic Clin Pharmacol Toxico</i>l. 2012;111(3):182-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22448718/pubmed" id="22448718" target="_blank">22448718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27881247">
<a name="27881247"></a>Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. <i>Am J Kidney Dis</i>. 2017;69(3):451-460. doi:10.1053/j.ajkd.2016.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/27881247/pubmed" id="27881247" target="_blank">27881247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30701615">
<a name="30701615"></a>Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. <i>Am J Addict</i>. 2019;28(2):55-62. doi:10.1111/ajad.12862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30701615/pubmed" id="30701615" target="_blank">30701615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880331">
<a name="21880331"></a>Lam J, Kelly L, Ciszkowski C, et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. <i>J Pediatr</i>. 2012;160(1):33-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/21880331/pubmed" id="21880331" target="_blank">21880331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30189012">
<a name="30189012"></a>Leuppi-Taegtmeyer A, Duthaler U, Hammann F, et al. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. <i>Nephrol Dial Transplant</i>. 2019;34(4):692-702. doi:10.1093/ndt/gfy285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30189012/pubmed" id="30189012" target="_blank">30189012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34286498">
<a name="34286498"></a>Lozano-López MT, Gamonal-Limcaoco S, Casado-Espada N, et al. Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: A systematic review. <i>Eur Rev Med Pharmacol Sci</i>. 2021;25(13):4554-4562. doi:10.26355/eurrev_202107_26248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/34286498/pubmed" id="34286498" target="_blank">34286498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35930693">
<a name="35930693"></a>Maffei MV, Laehn S, Bianchini M, Kim A. Risk factors associated with opioid/benzodiazepine iatrogenic withdrawal syndrome in COVID-19 acute respiratory distress syndrome. <i>J Pharm Pract</i>. 2022;8971900221116178. doi:10.1177/08971900221116178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35930693/pubmed" id="35930693" target="_blank">35930693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15322444">
<a name="15322444"></a>Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. <i>Clin J Pain</i>. 2004;20(5):363-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/15322444/pubmed" id="15322444" target="_blank">15322444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15153834">
<a name="15153834"></a>McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. <i>Cancer Control</i>. 2004;11(3 Suppl):3-9. doi:10.1177/10732748040110S302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/15153834/pubmed" id="15153834" target="_blank">15153834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35921640">
<a name="35921640"></a>Meek JY, Noble L; Section on Breastfeeding. Policy statement: Breastfeeding and the use of human milk. <i>Pediatrics.</i> 2022;150(1):e2022057988. doi:10.1542/peds.2022-057988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35921640/pubmed" id="35921640" target="_blank">35921640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9514554">
<a name="9514554"></a>Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. <i>Pain</i>. 1998;74(1):5-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/9514554/pubmed" id="9514554" target="_blank">9514554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35965031">
<a name="35965031"></a>Montandon G. The pathophysiology of opioid-induced respiratory depression. <i>Handb Clin Neurol</i>. 2022;188:339-355. doi:10.1016/B978-0-323-91534-2.00003-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35965031/pubmed" id="35965031" target="_blank">35965031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28034973">
<a name="28034973"></a>Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: A clinical guideline. <i>Pain Med</i>. 2017;18(10):1837-1863. doi:10.1093/pm/pnw255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28034973/pubmed" id="28034973" target="_blank">28034973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16870075">
<a name="16870075"></a>Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. <i>Curr Med Res Opin</i>. 2006;22(8):1503-1514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/16870075/pubmed" id="16870075" target="_blank">16870075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxaydo.1">
<a name="Oxaydo.1"></a>Oxaydo (oxycodone) [prescribing information]. Wayne, PA: Zyla Life Sciences US Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OxyContin.1">
<a name="OxyContin.1"></a>OxyContin (oxycodone) extended-release tablets [prescribing information]. Stamford, CT: Purdue Pharma LP; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxycodone.1">
<a name="Oxycodone.1"></a>Oxycodone hydrochloride capsules [prescribing information]. Allentown, PA: Genus Lifesciences Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxycodone.2">
<a name="Oxycodone.2"></a>Oxycodone hydrochloride 1 mg/mL oral solution [prescribing information]. Allentown, PA: Genus Lifesciences Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxycodone.3">
<a name="Oxycodone.3"></a>Oxycodone hydrochloride oral solution [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxycodone.4">
<a name="Oxycodone.4"></a>Oxycodone hydrochloride oral solution [prescribing information]. Largo, FL: VistaPharm; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxycodone.5">
<a name="Oxycodone.5"></a>Oxycodone hydrochloride tablet [prescribing information]. Coventry, RI: Rhodes Pharmaceuticals LP; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxy.1">
<a name="Oxy.1"></a>Oxy IR (oxycodone) [product monograph]. Toronto, Ontario, Canada: Purdue Pharma; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxyneo.1">
<a name="Oxyneo.1"></a>Oxyneo (oxycodone) controlled release tablets [product monograph]. Toronto, Ontario, Canada: Purdue Pharma; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21543825">
<a name="21543825"></a>Paice JA, Ferrell B. The management of cancer pain. <i>CA Cancer J Clin</i>. 2011;61(3):157-182. doi:10.3322/caac.20112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/21543825/pubmed" id="21543825" target="_blank">21543825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PAMI.1">
<a name="PAMI.1"></a>Pain Assessment and Management Initiative. Pain management &amp; dosing guide. <a href="https://pami.emergency.med.jax.ufl.edu/wordpress/files/2020/09/PAMI-Dosing-Guide-Nov.2.2020.pdf" target="_blank">https://pami.emergency.med.jax.ufl.edu/wordpress/files/2020/09/PAMI-Dosing-Guide-Nov.2.2020.pdf</a>. Updated November 2020. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11755892">
<a name="11755892"></a>Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. <i>Am J Surg</i>. 2001;182(suppl 5A):11S-18S. doi:10.1016/s0002-9610(01)00782-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/11755892/pubmed" id="11755892" target="_blank">11755892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33106341">
<a name="33106341"></a>Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn; Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. <i>Pediatrics</i>. 2020;146(5):e2020029074. doi:10.1542/peds.2020-029074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/33106341/pubmed" id="33106341" target="_blank">33106341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18456641">
<a name="18456641"></a>Pattinson KT. Opioids and the control of respiration. <i>Br J Anaesth</i>. 2008;100(6):747-758. doi:10.1093/bja/aen094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/18456641/pubmed" id="18456641" target="_blank">18456641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35189729">
<a name="35189729"></a>Pattullo GG. Clinical implications of opioid-induced ventilatory impairment. <i>Anaesth Intensive Care</i>. 2022;50(1-2):52-67. doi:10.1177/0310057X211070292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35189729/pubmed" id="35189729" target="_blank">35189729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pino.1">
<a name="Pino.1"></a>Pino CA, Wakerman SE. Prescription of opioids for acute pain in opioid naïve patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.1">
<a name="Portenoy.1"></a>Portenoy RK, Mehta Z, Ahmed E. Cancer pain management with opioids: optimizing analgesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25278772">
<a name="25278772"></a>Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. <i>Clin Exp Gastroenterol</i>. 2014;7:345-358. doi:10.2147/CEG.S52097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/25278772/pubmed" id="25278772" target="_blank">25278772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30992804">
<a name="30992804"></a>Rakoski M, Goyal P, Spencer-Safier M, Weissman J, Mohr G, Volk M. Pain management in patients with cirrhosis. <i>Clin Liver Dis (Hoboken)</i>. 2018;11(6):135-140. doi:10.1002/cld.711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30992804/pubmed" id="30992804" target="_blank">30992804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding other, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenquist.1">
<a name="Rosenquist.1"></a>Rosenquist R. Use of opioids in the management of chronic non-cancer pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30778756">
<a name="30778756"></a>Rossi M, Casale G, Badiali D, et al. Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert board. <i>Support Care Cancer</i>. 2019;27(11):4083-4090. doi:10.1007/s00520-019-04688-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/30778756/pubmed" id="30778756" target="_blank">30778756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roxicodone.1">
<a name="Roxicodone.1"></a>Roxicodone (oxycodone) [prescribing information]. Webster Groves, MO: SpecGx LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roxybond.1">
<a name="Roxybond.1"></a>Roxybond (oxycodone) [prescribing information]. Princeton, NJ: Protega Pharmaceuticals LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17550483">
<a name="17550483"></a>Seaton S, Reeves M, McLean S. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels. <i>Aust N Z J Obstet Gynaecol</i>. 2007;47(3):181-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/17550483/pubmed" id="17550483" target="_blank">17550483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19567715">
<a name="19567715"></a>Smith HS. Opioid metabolism. <i>Mayo Clin Proc</i>. 2009;84(7):613-624. doi:10.1016/S0025-6196(11)60750-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/19567715/pubmed" id="19567715" target="_blank">19567715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119438">
<a name="35119438"></a>Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. <i>Pediatr Crit Care Med</i>. 2022;23(2):e74-e110. doi:10.1097/PCC.0000000000002873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35119438/pubmed" id="35119438" target="_blank">35119438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36704210">
<a name="36704210"></a>Spadaro A, Faude S, Perrone J, et al. Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: A case series. <i>J Am Coll Emerg Physicians Open</i>. 2023;4(1):e12880. doi:10.1002/emp2.12880<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/36704210/pubmed" id="36704210" target="_blank">36704210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35623179">
<a name="35623179"></a>Spadaro A, Long B, Koyfman A, Perrone J. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. <i>Am J Emerg Med</i>. 2022;58:22-26. doi:10.1016/j.ajem.2022.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/35623179/pubmed" id="35623179" target="_blank">35623179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659261">
<a name="22659261"></a>Sulton-Villavasso C, Austin CA, Patra KP, et al. Index of suspicion. Case 1: Infant who has respiratory distress. Case 2: Abnormal behavior, seizures, and altered sensorium in a 7-year-old boy. Case 3: Fever and dysphagia in a 4-year-old girl. <i>Pediatr Rev</i>. 2012;33(6):279-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/22659261/pubmed" id="22659261" target="_blank">22659261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Supeudol.2019.09">
<a name="Supeudol.2019.09"></a>Supeudol (oxycodone) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15221581">
<a name="15221581"></a>Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. <i>Support Care Cancer</i>. 2004;12(9):613-618. doi:10.1007/s00520-004-0649-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/15221581/pubmed" id="15221581" target="_blank">15221581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25788766">
<a name="25788766"></a>Tawfic QA, Bellingham G. Postoperative pain management in patients with chronic kidney disease. <i>J Anaesthesiol Clin Pharmacol</i>. 2015;31(1):6-13. doi:10.4103/0970-9185.150518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/25788766/pubmed" id="25788766" target="_blank">25788766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25689360">
<a name="25689360"></a>Tran BW, Kohan LR, Vorenkamp KE. Postoperative oxycodone toxicity in a patient with chronic pain and end-stage renal disease. <i>A A Case Rep</i>. 2015;4(4):44-46. doi:10.1213/XAA.0000000000000115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/25689360/pubmed" id="25689360" target="_blank">25689360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20100280">
<a name="20100280"></a>Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. <i>Neurogastroenterol Motil</i>. 2010;22(4):424-e96. doi:10.1111/j.1365-2982.2009.01458.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/20100280/pubmed" id="20100280" target="_blank">20100280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS). HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. <a href="https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf" target="_blank">https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf</a>. Updated October 2019. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA drug safety communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>. Published April 13, 2023. Accessed April 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29029015">
<a name="29029015"></a>van der Schrier R, Jonkman K, van Velzen M, et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. <i>Br J Anaesth</i>. 2017;119(6):1169-1177. doi:10.1093/bja/aex295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/29029015/pubmed" id="29029015" target="_blank">29029015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28866754">
<a name="28866754"></a>Wang PP, Huang E, Feng X, et al. Opioid-associated iatrogenic withdrawal in critically ill adult patients: a multicenter prospective observational study. <i>Ann Intensive Care</i>. 2017;7(1):88. doi:10.1186/s13613-017-0310-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/28866754/pubmed" id="28866754" target="_blank">28866754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2458208">
<a name="2458208"></a>Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. <i>Clin Pharmacol Ther</i>. 1988;44(3):335-342. doi:10.1038/clpt.1988.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxycodone-drug-information/abstract-text/2458208/pubmed" id="2458208" target="_blank">2458208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xtampza.1">
<a name="Xtampza.1"></a>Xtampza ER (oxycodone) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals; March 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9729 Version 742.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
